Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | See Remarks | August 19, 2026 | August 21, 2026 |
| Verrica Pharmaceuticals Inc.VRCA · Entity 6823 | Chief Medical Officer | February 27, 2020 | March 02, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date August 19, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,592 |
Reported balance
After 2026-08-19 transaction · row 1
1 source rowRow 1 · 2026-08-19 · Sale · Disposed 1,697 · Balance 117,592 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
Verrica Pharmaceuticals Inc.
Report date February 27, 2020 · Filed March 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.81 · Expires 2030-02-26 | Direct | 55,000 |
Reported balance
After 2020-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-27 · Grant · Acquired 55,000 · Balance 55,000 F1: 25% of the total shares subject to the option shall vest on February 27, 2021 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the total shares subject to the option shall vest on February 27, 2021 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2025 Filed Mar 5, 2025 00:44 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 99,000 | $0.00 Strike: $13.69 | $0.00 |
DisclosureSEC source: 0001787306-25-000043 · wk-form4_1741135437.xml · derivative · entry 5 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,000 Underlying: Common Stock · 99,000 shares Expires 2035-02-28 F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:44 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-25-000043 · wk-form4_1741135437.xml · nonDerivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169,862 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:44 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 38,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-25-000043 · wk-form4_1741135437.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,862 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 01:00 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 12,116 | $12.70 | $153,873.20 |
DisclosureSEC source: 0001787306-25-000014 · wk-form4_1738717243.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,862 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligation in connection with the vesting of Restricted Stock Units ("RSUs"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.545 to $13.0096, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 31, 2024 Filed Dec 31, 2024 23:13 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,691 | $14.00 | $23,674.00 |
DisclosureSEC source: 0001787306-24-000174 · wk-form4_1735686824.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,978 F1 · shares: The transaction reported in this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units ("RSUs"), granted on August 3, 2020. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $13.8068 to $14.40, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 21:21 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 16,023 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001787306-24-000161 · wk-form4_1732656053.xml · derivative · entry 3 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,500 Underlying: Common Stock · 16,023 shares Expires 2034-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 21:21 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 16,023 | $10.14 | $162,514.88 |
DisclosureSEC source: 0001787306-24-000161 · wk-form4_1732656053.xml · nonDerivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,669 F1 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $10.205 to $10.14, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 21:21 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 16,023 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-24-000161 · wk-form4_1732656053.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 00:04 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 100 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001787306-24-000157 · wk-form4_1731974656.xml · derivative · entry 7 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,523 Underlying: Common Stock · 100 shares Expires 2034-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 00:04 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 100 | $10.03 | $1,003.00 |
DisclosureSEC source: 0001787306-24-000157 · wk-form4_1731974656.xml · nonDerivative · entry 5 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,669 Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 00:04 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-24-000157 · wk-form4_1731974656.xml · nonDerivative · entry 4 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2024 Filed Nov 19, 2024 00:04 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 18,377 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001787306-24-000157 · wk-form4_1731974656.xml · derivative · entry 6 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,623 Underlying: Common Stock · 18,377 shares Expires 2034-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 14, 2024 Filed Nov 19, 2024 00:04 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 18,377 | $10.29 | $189,182.03 |
DisclosureSEC source: 0001787306-24-000157 · wk-form4_1731974656.xml · nonDerivative · entry 3 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,669 F1 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $10.4926 to $10.00, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 14, 2024 Filed Nov 19, 2024 00:04 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 18,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-24-000157 · wk-form4_1731974656.xml · nonDerivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2024 Filed Nov 19, 2024 00:04 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 50,749 | $10.29 | $522,435.58 |
DisclosureSEC source: 0001787306-24-000157 · wk-form4_1731974656.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,669 F1 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $10.4926 to $10.00, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 21:45 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 15,441 | $8.68 | $134,092.73 |
DisclosureSEC source: 0001787306-24-000142 · wk-form4_1730843144.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 179,418 F1 · shares: The sale was made pursuant to the Issuer's mandatory sell-to-cover requirements implemented to satisfy the tax withholding obligations associated with the vesting of the Reporting Person's Restricted Stock Units ("RSUs"). F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $8.32 to $8.86, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:39 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,728 | $8.29 | $14,318.21 |
DisclosureSEC source: 0001787306-24-000128 · wk-form4_1724272751.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,859 F1 · kind: The sale was made pursuant to the Issuer's mandatory sell-to-cover requirements implemented to satisfy the tax withholding obligations associated with the vesting of the reporting person's Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $8.27 to $8.30, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 02, 2024 Filed Aug 5, 2024 20:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 13,206 | $9.02 | $119,106.23 |
DisclosureSEC source: 0001787306-24-000117 · wk-form4_1722890238.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 196,587 F1 · shares: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $8.74 to $9.26, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 30, 2024 Filed May 31, 2024 20:50 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 23,000 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001787306-24-000085 · wk-form4_1717188632.xml · derivative · entry 4 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,000 Underlying: Common Stock · 23,000 shares Expires 2034-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 30, 2024 Filed May 31, 2024 20:50 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 23,000 | $8.75 | $201,319.00 |
DisclosureSEC source: 0001787306-24-000085 · wk-form4_1717188632.xml · nonDerivative · entry 3 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,793 F2 · price: The transaction was executed in multiple trades in prices ranging from $8.70 to $8.88, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 30, 2024 Filed May 31, 2024 20:50 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-24-000085 · wk-form4_1717188632.xml · nonDerivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2024 Filed May 31, 2024 20:50 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 49,952 | $8.72 | $435,386.63 |
DisclosureSEC source: 0001787306-24-000085 · wk-form4_1717188632.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,793 F1 · price: The transaction was executed in multiple trades in prices ranging from $8.50 to $8.85, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 02, 2024 Filed May 3, 2024 20:22 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 9,555 | $8.74 | $83,489.68 |
DisclosureSEC source: 0001787306-24-000068 · wk-form4_1714767714.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 259,745 F1 · shares: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligation in connection with the vesting of Restricted Stock Units. F2 · price: The transaction was executed in multiple trades in prices ranging from $8.47 to $9.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 22:12 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 4,782 | $11.12 | $53,181.58 |
DisclosureSEC source: 0001787306-24-000040 · wk-form4_1709763131.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 269,300 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The transaction was executed in multiple trades in prices ranging from $11.000 to $11.3200, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:36 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Disposition to issuerStock Option (right to buy) · Derivative | 55,800 | Not disclosed Strike: $15.82 | Not disclosed |
DisclosureSEC source: 0001787306-24-000020 · wk-form4_1708040155.xml · derivative · entry 8 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,800 shares Expires 2033-03-02 F4 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 2, 2023, and received in exchange for the option, these RSUs that vest in twelve equal quarterly installments commencing May 1, 2024. F8 · derivative.exercise_date: The canceled option vest as to 1/48 of the shares subject to the option vest on each monthly anniversary measured from March 1, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:36 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Disposition to issuerStock Option (right to buy) · Derivative | 47,100 | Not disclosed Strike: $17.67 | Not disclosed |
DisclosureSEC source: 0001787306-24-000020 · wk-form4_1708040155.xml · derivative · entry 7 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,100 shares Expires 2032-03-03 F3 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2022, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024. F7 · derivative.exercise_date: The canceled option vest as to 1/48 of the shares subject to the option vest on each monthly anniversary measured from March 1, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:36 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Disposition to issuerStock Option (right to buy) · Derivative | 28,800 | Not disclosed Strike: $32.44 | Not disclosed |
DisclosureSEC source: 0001787306-24-000020 · wk-form4_1708040155.xml · derivative · entry 6 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,800 shares Expires 2031-03-02 F2 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2021, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024 F6 · derivative.exercise_date: The canceled option vest as to 1/48 of the shares subject to the option vest on each monthly anniversary measured from March 3, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:36 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Disposition to issuerStock Option (right to buy) · Derivative | 320,000 | Not disclosed Strike: $25.89 | Not disclosed |
DisclosureSEC source: 0001787306-24-000020 · wk-form4_1708040155.xml · derivative · entry 5 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 320,000 shares Expires 2030-08-03 F1 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on August 3, 2020, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in four equal quarterly installments commencing May 1, 2024. F5 · derivative.exercise_date: The canceled option vested as to 1/4 of the total shares on August 1, 2021, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vesting on August 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:36 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 27,900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001787306-24-000020 · wk-form4_1708040155.xml · nonDerivative · entry 4 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,082 F4 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 2, 2023, and received in exchange for the option, these RSUs that vest in twelve equal quarterly installments commencing May 1, 2024. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:36 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 23,550 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001787306-24-000020 · wk-form4_1708040155.xml · nonDerivative · entry 3 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,182 F3 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2022, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:36 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 9,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001787306-24-000020 · wk-form4_1708040155.xml · nonDerivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,632 F2 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2021, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024 Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:36 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 128,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001787306-24-000020 · wk-form4_1708040155.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,032 F1 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on August 3, 2020, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in four equal quarterly installments commencing May 1, 2024. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 21:35 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 276,000 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001787306-24-000012 · wk-form4_1705527338.xml · derivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,000 Underlying: Common Stock · 276,000 shares Expires 2034-01-12 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 21:35 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-24-000012 · wk-form4_1705527338.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,032 F1 · shares: Constitute Restricted Stock Units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year, beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 22:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,325 | $3.54 | $4,691.56 |
DisclosureSEC source: 0001787306-24-000002 · wk-form4_1704321036.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,032 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units ("RSUs"), granted on August 3, 2020. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units ("RSUs"), granted on August 3, 2020. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| August 21, 2023 Filed Aug 22, 2023 16:24 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,305 | $7.04 | $9,187.20 |
DisclosureSEC source: 0001787306-23-000083 · wk-form4_1692721462.xml · nonDerivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,357 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units ("RSUs"), granted on August 3, 2020. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| August 21, 2023 Filed Aug 22, 2023 16:24 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 300 | $7.05 | $2,115.00 |
DisclosureSEC source: 0001787306-23-000083 · wk-form4_1692721462.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,662 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units ("RSUs"), granted on August 3, 2020. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 21:28 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 851 | $15.26 | $12,989.15 |
DisclosureSEC source: 0001567619-23-004670 · doc1.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,962 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The transaction was executed in multiple trades in prices ranging from $15.120 to $15.440, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 55,800 | $0.00 Strike: $15.82 | $0.00 |
DisclosureSEC source: 0001567619-23-004541 · doc1.xml · derivative · entry 4 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,800 Underlying: Common Stock · 55,800 shares Expires 2033-03-02 F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-004541 · doc1.xml · nonDerivative · entry 3 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,813 F3 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 2 of each year, beginning March 2, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 23 | $16.52 | $379.96 |
DisclosureSEC source: 0001567619-23-004541 · doc1.xml · nonDerivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,813 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,728 | $15.82 | $27,333.16 |
DisclosureSEC source: 0001567619-23-004541 · doc1.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,836 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The transaction was executed in multiple trades in prices ranging from $15.470 to $16.460, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 22:15 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,475 | $15.01 | $22,136.06 |
DisclosureSEC source: 0001787306-23-000002 · wf-form4_167287050853068.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,564 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units ("RSUs"), granted on August 3, 2020. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units ("RSUs"), granted on August 3, 2020. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| August 18, 2022 Filed Mar 4, 2026 01:41 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 16,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014324 · wk-form4_1772588506.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,401 F1 · kind: On August 8, 2020, the Reporting Person was granted performance-based Restricted Stock Units ("RSUs") subject to a milestone condition. The Compensation Committee of the Issuer certified the achievement of the milestone and commencement of vesting on August 18, 2022. The remaining RSUs vested in three substantially equal annual installments, such that the RSUs fully vested on August 18, 2025. F2 · balance_after: Reflects holdings following the August 18, 2022 transaction reported herein. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 01:53 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 30 | $16.44 | $493.35 |
DisclosureSEC source: 0001567619-22-006497 · doc1.xml · nonDerivative · entry 3 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,039 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). F4 · price: The transaction was executed in multiple trades in prices ranging from $16.44 to $16.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F5 · balance_after: Includes 41,675 RSUs. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 01:53 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 981 | $16.86 | $16,538.78 |
DisclosureSEC source: 0001567619-22-006497 · doc1.xml · nonDerivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,069 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). F3 · price: The transaction was executed in multiple trades in prices ranging from $16.63 to $17.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 01:53 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 47,100 | $0.00 Strike: $17.67 | $0.00 |
DisclosureSEC source: 0001567619-22-006497 · doc1.xml · derivative · entry 4 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,100 Underlying: Common Stock · 47,100 shares Expires 2032-03-03 F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 3, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 01:53 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 17,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006497 · doc1.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,050 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 3 of each year, beginning March 3, 2023, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| December 30, 2021 Filed Jan 5, 2022 02:05 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 16,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000389 · doc1.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 F1 · shares: On August 3, 2020, the Reporting Person was granted performance-based restricted stock units ("RSUs") subject to a milestone condition. The Compensation Committee of the Issuer certified the achievement of the milestone and commencement of vesting on December 30, 2021 (the "Milestone Vesting Commencement Date"). 25% of the performance-based RSUs shall vest annually from the Milestone Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 26,250 RSUs. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 20:54 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 28,800 | $0.00 Strike: $32.44 | $0.00 |
DisclosureSEC source: 0001567619-21-005733 · doc1.xml · derivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,800 Underlying: Common Stock · 28,800 shares Expires 2031-03-03 F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 3, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.